EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Development of oncolytic and gene therapy vectors based on adenovirus serotype 4 as an alternative to adenovirus serotype 5

Erwan Sallard, Lukas Schulte, Alexander van den Boom, Alexander Klimovitskii, Julius Knierer, Claudia Hagedorn, Maximilian Knocks, Wenli Zhang, Florian Kreppel, Anja Ehrhardt, Eric Ehrke-Schulz iD

The Journal of Gene Medicine · 2024

DOI: 10.1002/jgm.3576 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2024. Verfasst von Erwan Sallard und 10 weiteren Autor:innen. Beteiligte Einrichtung: Virology and Microbiology, Center for Biomedical Education and Research (ZBAF), Department of Human Medicine, Faculty of Health, Witten/Herdecke Univ…. Hauptthemen laut MEDLINE: Papillomavirus Infections, Adenoviruses, Human, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Duchenne Stiftung, Stiftung Tumorforschung-Kopf-Hals, DFG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adenoviral vectors are among the most frequently used vectors for gene therapy and cancer treatment. Most vectors are derived from human adenovirus (Ad) serotype 5 despite limited applicability caused by pre‐existing immunity and unfavorable liver tropism, whereas the other more than 100 known human serotypes remain largely unused. Here, we screened a library of human Ad types and identified Ad4 as a promising candidate vector.

Methods

Reporter‐gene‐expressing viruses representative of the natural human Ad diversity were used to transduce an array of muscle cell lines and two‐ or three‐dimensional tumor cultures. The time‐course of transgene expression was monitored by fluorescence or luminescence measurements. To generate replication‐deficient Ad4 vector genomes, successive homologous recombination was applied.

Results

Ad4, 17 and 50 transduced human cardiomyocytes more efficiently than Ad5, whereas Ad37 was found to be superior in rhabdomyocytes. Despite its moderate transduction efficiency, Ad4 showed efficient and long‐lasting gene expression in papillomavirus (HPV) positive tumor organoids. Therefore, we aimed to harness the potential of Ad4 for improved muscle transduction or oncolytic virotherapy of HPV‐positive tumors. We deleted the E1 and E3 transcription units to produce first generation Ad vectors for gene therapy. The E1‐ and E1/E3‐deleted vectors were replication‐competent in HEK293 cells stably expressing E1 but not in the other cell lines tested. Furthermore, we show that the Ad5 E1 transcription unit can complement the replication of E1‐deleted Ad4 vectors.

Conclusions

Our Ad4‐based gene therapy vector platform contributes to the development of improved Ad vectors based on non‐canonical serotypes for a broad range of applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsAdenoviruses, HumanNeoplasmsHumansSerogroupHEK293 CellsAdenoviridaeGenetic VectorsGenetic Therapy

Stichwörter der Autor:innen

adenovirusfirst-generation adenovirus vectorgene therapyhuman adenovirus type 4oncolytic virusserotypevirotherapy

Autor:innen und Institutionen

  • Virology and Microbiology, Center for Biomedical Education and Research (ZBAF), Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.
  • Institute for Biochemistry and Molecular Medicine, Center for Biomedical Education and Research (ZBAF), Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.

ORCID-Profile: Eric Ehrke-Schulz

Förderung

  • Deutsche Duchenne Stiftung
  • Stiftung Tumorforschung-Kopf-Hals
  • DFG
  • California Department of Fish and Game

Zitieren

APA

Sallard, E., Schulte, L., van den Boom, A., Klimovitskii, A., Knierer, J., Hagedorn, C., Knocks, M., Zhang, W., Kreppel, F., Ehrhardt, A., & Ehrke-Schulz, E. (2024). Development of oncolytic and gene therapy vectors based on adenovirus serotype 4 as an alternative to adenovirus serotype 5. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3576

Vancouver

Sallard E, Schulte L, van den Boom A, Klimovitskii A, Knierer J, Hagedorn C, et al. Development of oncolytic and gene therapy vectors based on adenovirus serotype 4 as an alternative to adenovirus serotype 5. The Journal of Gene Medicine. 2024. doi:10.1002/jgm.3576

BibTeX
@article{Sallard2024,
  author = {Sallard, Erwan and Schulte, Lukas and van den Boom, Alexander and Klimovitskii, Alexander and Knierer, Julius and Hagedorn, Claudia and Knocks, Maximilian and Zhang, Wenli and Kreppel, Florian and Ehrhardt, Anja and Ehrke-Schulz, Eric},
  title = {Development of oncolytic and gene therapy vectors based on adenovirus serotype 4 as an alternative to adenovirus serotype 5},
  journal = {The Journal of Gene Medicine},
  year = {2024},
  doi = {10.1002/jgm.3576}
}
Kostenlos starten →